0000000000905771

AUTHOR

Didier Blanchard

showing 2 related works from this author

Temporal Trends in Transcatheter Aortic Valve Replacement in France

2017

Background - Transcatheter aortic valve replacement (TAVR) is standard therapy for patients with severe aortic stenosis who are at high surgical risk. However, national data regarding procedural characteristics and clinical outcomes over time are limited. Objectives - The aim of this study was to assess nationwide performance trends and clinical outcomes of TAVR during a 6-year period. Methods - TAVRs performed in 48 centers across France between January 2013 and December 2015 were prospectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry. Findings were further compared with those reported from the FRANCE 2 (French Aortic National CoreValve and Edwa…

Aortic valvemedicine.medical_specialtymedicine.medical_treatmentnational registry030204 cardiovascular system & hematologyoutcomes03 medical and health sciences0302 clinical medicineValve replacementCardiac tamponadeMedicine030212 general & internal medicineComputingMilieux_MISCELLANEOUSAortic dissectionbusiness.industryMortality ratetransfemoralEuroSCORE[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseasepacemaker3. Good healthSurgeryStenosisCathetermedicine.anatomical_structureCardiology and Cardiovascular Medicinebusiness
researchProduct

β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study.

2016

OBJECTIVE To assess the association between early and prolonged beta blocker treatment and mortality after acute myocardial infarction. DESIGN Multicentre prospective cohort study. SETTING Nationwide French registry of Acute ST- and non-STelevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS 2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction. MAIN OUTCOME MEASURES Mortality was assessed at 30 days in relation to early use of beta blockers (<= 48 hours of admission), at one year in relation to discharge prescription, and at five years in relation to one year use. RESULTS beta blockers were…

MaleTime FactorsMyocardial Infarction030204 cardiovascular system & hematologyCorrectionsCohort Studies0302 clinical medicineMedicine030212 general & internal medicineMyocardial infarctionProspective StudiesProspective cohort studyHazard ratioGeneral MedicineMiddle AgedMetaanalysisPatient Discharge3. Good healthManagementImpactAcute DiseaseCardiologyFemaleLife Sciences & Biomedicinemedicine.medical_specialtyRegistrySt-Segment-Elevationmedicine.drug_classAdrenergic beta-AntagonistsGuidelines03 medical and health sciencesMedicine General & InternalFast-MiInternal medicineGeneral & Internal Medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyClinical-OutcomesHumansBeta blockerSurvival analysisAgedProportional Hazards ModelsHeart FailureScience & Technologybusiness.industryProportional hazards modelResearchCoronary Care Unitsmedicine.diseaseSurvival AnalysisDiscontinuationLogistic ModelsAdherenceHeart failureTherapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBMJ (Clinical research ed.)
researchProduct